Phenotyping of mice with heart specific overexpression of A<sub>2A</sub>-adenosine receptors:Evidence for cardioprotective effects of A<sub>2A</sub>-adenosine receptors by Boknik, Peter et al.
 
 
University of Birmingham
Phenotyping of mice with heart specific
overexpression of A2A-adenosine receptors
Boknik, Peter; Drzewiecki, Katharina; Eskandar, John; Gergs, Ulrich; Grote-Wessels,
Stephanie; Fabritz, Larissa; Kirchhof, Paulus; Müller, Frank U.; Stümpel, Frank; Schmitz,
Wilhelm; Zimmermann, Norbert; Kirchhefer, Uwe; Neumann, Joachim
DOI:
10.3389
10.3389/fphar.2018.00013
10.3389/fphar.2018.00013
License:
Creative Commons: Attribution (CC BY)
Document Version
Publisher's PDF, also known as Version of record
Citation for published version (Harvard):
Boknik, P, Drzewiecki, K, Eskandar, J, Gergs, U, Grote-Wessels, S, Fabritz, L, Kirchhof, P, Müller, FU, Stümpel,
F, Schmitz, W, Zimmermann, N, Kirchhefer, U & Neumann, J 2018, 'Phenotyping of mice with heart specific
overexpression of A2A-adenosine receptors: Evidence for cardioprotective effects of A2A-adenosine receptors',Frontiers in Pharmacology, vol. 9, no. JAN, 13. https://doi.org/10.3389,
https://doi.org/10.3389/fphar.2018.00013, https://doi.org/10.3389/fphar.2018.00013
Link to publication on Research at Birmingham portal
Publisher Rights Statement:
Checked for eligibility: 23/01/2018
This Document is Protected by copyright and was first published by Frontiers. All rights reserved. it is reproduced with permission.
General rights
Unless a licence is specified above, all rights (including copyright and moral rights) in this document are retained by the authors and/or the
copyright holders. The express permission of the copyright holder must be obtained for any use of this material other than for purposes
permitted by law.
•	Users may freely distribute the URL that is used to identify this publication.
•	Users may download and/or print one copy of the publication from the University of Birmingham research portal for the purpose of private
study or non-commercial research.
•	User may use extracts from the document in line with the concept of ‘fair dealing’ under the Copyright, Designs and Patents Act 1988 (?)
•	Users may not further distribute the material nor use it for the purposes of commercial gain.
Where a licence is displayed above, please note the terms and conditions of the licence govern your use of this document.
When citing, please reference the published version.
Take down policy
While the University of Birmingham exercises care and attention in making items available there are rare occasions when an item has been
uploaded in error or has been deemed to be commercially or otherwise sensitive.
If you believe that this is the case for this document, please contact UBIRA@lists.bham.ac.uk providing details and we will remove access to
the work immediately and investigate.
Download date: 01. Mar. 2020
fphar-09-00013 January 18, 2018 Time: 17:55 # 1
ORIGINAL RESEARCH
published: 22 January 2018
doi: 10.3389/fphar.2018.00013
Edited by:
Francisco Ciruela,
University of Barcelona, Spain
Reviewed by:
Jason N. Peart,
Griffith University, Australia
Andrew F. James,
University of Bristol, United Kingdom
*Correspondence:
Joachim Neumann
joachim.neumann@medizin.
uni-halle.de
Ulrich Gergs
ulrich.gergs@medizin.uni-halle.de
Specialty section:
This article was submitted to
Experimental Pharmacology and
Drug Discovery,
a section of the journal
Frontiers in Pharmacology
Received: 06 November 2017
Accepted: 05 January 2018
Published: 22 January 2018
Citation:
Boknik P, Drzewiecki K, Eskandar J,
Gergs U, Grote-Wessels S, Fabritz L,
Kirchhof P, Müller FU, Stümpel F,
Schmitz W, Zimmermann N,
Kirchhefer U and Neumann J (2018)
Phenotyping of Mice with Heart
Specific Overexpression
of A2A-Adenosine Receptors:
Evidence for Cardioprotective Effects
of A2A-Adenosine Receptors.
Front. Pharmacol. 9:13.
doi: 10.3389/fphar.2018.00013
Phenotyping of Mice with Heart
Specific Overexpression of
A2A-Adenosine Receptors: Evidence
for Cardioprotective Effects of
A2A-Adenosine Receptors
Peter Boknik1, Katharina Drzewiecki1, John Eskandar1, Ulrich Gergs2* ,
Stephanie Grote-Wessels1, Larissa Fabritz3, Paulus Kirchhof3, Frank U. Müller1,
Frank Stümpel1, Wilhelm Schmitz1, Norbert Zimmermann4, Uwe Kirchhefer1 and
Joachim Neumann2*
1 Institut für Pharmakologie und Toxikologie, Universitätsklinikum Münster, Westfälische Wilhelms-Universität, Münster,
Germany, 2 Institut für Pharmakologie und Toxikologie, Medizinische Fakultät, Martin-Luther-Universität Halle-Wittenberg,
Halle, Germany, 3 Centre for Cardiovascular Sciences, University of Birmingham, Birmingham, United Kingdom,
4 Bundesinstitut für Arzneimittel und Medizinprodukte, Bonn, Germany
Background: Adenosine can be produced in the heart and acts on cardiac adenosine
receptors. One of these receptors is the A2A-adenosine receptor (A2A-AR).
Methods and Results: To better understand its role in cardiac function, we
generated and characterized mice (A2A-TG) which overexpress the human A2A-AR in
cardiomyocytes. In isolated atrial preparations from A2A-TG but not from WT, CGS
21680, an A2A-AR agonist, exerted positive inotropic and chronotropic effects. In
ventricular preparations from A2A-TG but not WT, CGS 21680 increased the cAMP
content and the phosphorylation state of phospholamban and of the inhibitory subunit
of troponin in A2A-TG but not WT. Protein expression of phospholamban, SERCA,
triadin, and junctin was unchanged in A2A-TG compared to WT. Protein expression
of the α-subunit of the stimulatory G-protein was lower in A2A-TG than in WT but
expression of the α-subunit of the inhibitory G-protein was higher in A2A-TG than
in WT. While basal hemodynamic parameters like left intraventricular pressure and
echocardiographic parameters like the systolic diameter of the interventricular septum
were higher in A2A-TG than in WT, after β-adrenergic stimulation these differences
disappeared. Interestingly, A2A-TG hearts sustained global ischemia better than WT.
Conclusion: We have successfully generated transgenic mice with cardiospecific
overexpression of a functional A2A-AR. This receptor is able to increase cardiac function
per se and after receptor stimulation. It is speculated that this receptor may be useful to
sustain contractility in failing human hearts and upon ischemia and reperfusion.
Keywords: A2A-adenosine receptor, contractility, ischemia, reperfusion, protein phosphorylation
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INTRODUCTION
Adenosine elicits multiple effects in the human body. These
include effects on cardiac function that have been studied
for many years and some effects of adenosine including the
downstream signaling mechanisms are similar to those of vagal
stimulation. For example, the negative chronotropic effect on the
sinus node, the negative dromotropic effect on the AV-node, and
the negative inotropic effect in atrial tissue of adenosine (Shryock
and Belardinelli, 1997). Extracellular adenosine acts on A1-, A2-,
and A3-adenosine receptors (AR). Typically, A1-AR inhibits and
A2-AR stimulates adenylyl cyclase activities (Olsson and Pearson,
1990). The A2A-AR was the first of the P1-purinoceptor family to
be cloned (Libert et al., 1989).
The negative inotropic effects of adenosine in the rat atrium
were mediated by inhibition of adenylyl cyclase activity followed
by a decreased cAMP content (Linden et al., 1985). But in guinea
pig atrium, no adenosine-induced decrease in cAMP content
was found (Böhm et al., 1984). Here, the negative inotropic
effect of adenosine was inhibited by pertussis toxin (Böhm
et al., 1986) and therefore mediated by a pertussis toxin-sensitive
G-protein. Probably, an enhanced conductance of potassium in
the sarcolemma was involved (Belardinelli and Isenberg, 1983).
However, the activation of protein phosphatases has also been
suggested (Gupta et al., 1993a,b).
In contrast, in the ventricle of most species, adenosine is
nearly ineffective to influence force of contraction but via
activation of A1-adenosine receptors, it can decrease the effects of
β-adrenergic stimulation or in other words the inotropic effects of
cAMP-elevating agents are decreased by adenosine [for example
forskolin or phosphodiesterase inhibitors; rat (Dobson, 1978,
1983) or guinea pig (Böhm et al., 1984; Brückner et al., 1985)].
Adenosine can also provoke relaxation of the vasculature via
activation of A2A-AR on smooth muscle cells [human coronaries
(Makujina et al., 1992)].
Adenosine is produced in cardiomyocytes and its release there
is markedly enhanced during β-adrenergic stimulation, ischemia,
or necrosis. In the clinic, adenosine and its precursor ATP can
be used to stop supraventricular arrhythmias and therefore, the
effects of adenosine in the mammalian heart are of clinical
relevance and should be further investigated. It is controversial
and may be species dependent (or method dependent) whether
A2A-AR is functional (increase in cAMP, increase in contractility)
in the mammalian heart: some reported a lack of effect [rat
(Shryock et al., 1993), guinea-pig (Boknik et al., 1997), rabbit
(Kilpatrick et al., 2002)] whereas other reported a functional
response [mouse (Morrison et al., 2006), rat (Monahan et al.,
2000)].
It is important to note, that A2A-receptors in human hearts
have been detected on the protein level (Marala and Mustafa,
1998). Moreover, work in isolated perfused A2A-KO (constitutive
deletion) mouse hearts clearly established that CGS 21680 a
classical A2A-receptor agonist was selective: only in WT hearts
CGS 21680 (up to 1 µM) increased contractility but not in hearts
from A2A-KO mice (Ledent et al., 1997). However, under basal
conditions (no CGS 21680 given) contractility of WT and KO
were not different (Ledent et al., 1997; Ashton et al., 2017),
suggesting that CGS 21680 is an appropriate tool to assess A2A
function in mice. Moreover, there is evidence that A2A-receptor
stimulation can protect the heart against reperfusion injury [e.g.,
rat (Cargnoni et al., 1999)].
As part of our long-standing effort to characterize all known
adenosine receptors in the mammalian heart, we report here on
the generation and phenotyping of a novel transgenic mouse
model in which we successfully expressed an inotropically active
A2A-AR. We used this model to study reperfusion injury in
the isolated perfused heart. A progress report of this work has
appeared as abstract (Grote-Wessels et al., 2007).
MATERIALS AND METHODS
Isolation of A2A-Receptor cDNA and
Generation of Transgenic Mice
The investigation conforms to the Guide for the Care and Use of
Laboratory Animals published by the National Research Council
(2011). Animals were handled and maintained to according
to approved protocols of the animal welfare committee of the
University of Münster, Germany.
The PCR generated human A2A-AR cDNA fragment
containing a 3′ and 5′ engineered NotI digestion site was
inserted into a mouse cardiac α-myosin heavy chain promoter
expression cassette via NotI. The orientation of the cDNA
was confirmed by sequencing. The A2A-AR cDNA promoter
construct was digested with NruI and purified by a cesium
chloride gradient centrifugation for injection into the pronuclei
of single-cell fertilized mouse embryos. Generation of transgenic
(A2A-TG) mice was performed by standard procedures (mouse
strain: FVB/N). One transgenic line overexpressing the A2A-
AR under the control of the α-myosin heavy chain (MHC)
promoter was established, which was investigated in the present
study. Genotypes were identified by PCR analyses of tail-tip
DNA using the following primers 5′-acaaagcaggcgatgaag-3′
and 5′-acccttaccccacatagacc-3′. For the reverse transcription
4 µg RNA and random primers were used (Transcriptor
High Fidelity cDNA Synthesis Kit, Roche Applied Science,
Mannheim, Germany). The PCR reaction was performed
using the Ampliqon Taq DNA polymerase (Biomol, Hamburg,
Germany) according to the manufacturer’s instructions. For all
experiments, 12–30 weeks old A2A-TG mice and WT littermates
of both sexes were used.
Western Blot Analysis
Homogenates from ventricular tissue samples were prepared in
300 µl of 10 mM NaHCO3 and 100 µl 20% SDS. Crude extracts
were incubated at 25◦C for 30 min before centrifugation to
remove debris and thereafter, the supernatants (= homogenates)
were separated and stored at −20◦C until further use. Western
blot analysis was performed as previously described (Gergs
et al., 2004). Briefly, aliquots of 100 µg of protein were loaded
per lane and finally, bands were detected using enhanced
chemifluorescence (ECF, GE Healthcare, Munich, Germany)
together with a StormTM PhosphorImager (GE Healthcare,
Munich, Germany). Following primary antibodies were used
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in this study: polyclonal rabbit anti calsequestrin, monoclonal
mouse anti SERCA2a, polyclonal rabbit anti triadin, and
polyclonal rabbit anti junctin (all kindly provided by L.R.
Jones, Indianapolis, IN, United States), monoclonal mouse
anti PLB (A-1, Badrilla, Leeds, United Kingdom), polyclonal
rabbit anti phospho-PLB (antibodies were raised against PLB-
peptide phosphorylated at serine-16 or at threonine-17, Badrilla,
Leeds, United Kingdom). The characteristics and use of these
antibodies has been reported repeatedly by our group (Kirchhefer
et al., 2002). The antibodies against TnI and phosphor-TnI
were obtained from GE Healthcare (Freiburg, Germany), the
antibodies against α-subunits of Gi-protein and Gs-protein were
purchased from Calbiochem (Darmstadt, Germany).
Histological Analysis
Hearts were fixed in buffered 4% formaldehyde and embedded
in paraffin. Four micron sections were mounted on polylysine
microslides, dewaxed in xylene, rehydrated in sequential
decreasing alcohol concentrations and pre-treated in Tris/EDTA-
buffer, pH 9 in a pressure cooker for antigen retrieval. After
blocking endogenous mouse IgG with Fab Fragment of goat IgG
directed against mouse IgG (100 µg mL−1, Dianova, Hamburg,
Germany) for 1 h at room temperature and washing slides were
incubated with mouse primary monoclonal antibody to A2A-AR
(clone 7F6-G5-A2, 5 µg ml−1, Upstate, NY, United States).
For detection a goat-anti-mouse antibody conjugated to Alexa
Fluor 594 (1:300, Dianova, Hamburg, Germany) was used.
Finally, samples were counterstained for approximately 15 s
with DAPI and mounted with Vectashield (Vector Laboratories,
Burlingame, CA, United States). For imaging a Zeiss Axiophot2
microscope was used, separate color images (blue for DAPI, red
for Alexa 594) were merged by AxioVision multichannel image
processing (Carl Zeiss Vision GmbH, Germany). Images shown
are representative of at least five independent experiments, which
gave similar results (Buchwalow et al., 2004).
Echocardiography
Echocardiography in spontaneously breathing mice was
performed under anesthesia with 1.5% isoflurane as described
previously (Gergs et al., 2010).
Left-Ventricular Catheterization
Mice were anesthetized by i.p. injection of avertin (2,2,2-
tribromoethanol, Sigma–Aldrich) in 2% solution at a dose of
400 mg kg−1 bodyweight and placed on a controlled heating pad
(Föhr Medical Instruments, Seeheim-Ober Beerbach, Germany)
in supine position. Additional doses of avertin (each 10% of
the initial dose) were applied during experiments if appropriate
to maintain depth of anesthesia. A miniature pressure-volume
catheter (model SPR-839, Millar Instruments, Houston, TX,
United States) was inserted via the right carotid artery and
placed in the left ventricle. Increasing doses of dobutamine
were administered into the cannulated left external jugular
vein using an automated syringe pump (B. Braun, Melsungen,
Germany). Data were recorded using the MPVS-400 system
(Millar Instruments) and Chart5 software (ADInstruments, Bella
Vista, NSW, Australia). At the end of experiments, animals were
euthanized by avertin overdose, and hearts were excised, weighed,
and stored at −80◦C until further examination. Hemodynamic
data were analyzed using Chart5 software (ADInstruments) and
PVAN software (Millar Instruments).
Isolation of Cardiomyocytes
Ventricular cardiomyocytes were isolated using a published
protocol (Kirchhefer et al., 2002). In brief, hearts were perfused
for 5 min at 2 ml min−1 with a Ca2+-free solution (solution A)
composed of (in mM) 140 NaCl, 5.8 KCl, 0.5 KH2PO4, 0.4
NaH2PO4, 0.9 MgSO4, 10 HEPES, 11.1 glucose (pH 7.1).
Thereafter, hearts were perfused for 30 min with solution A
supplemented with 0.2 mg ml−1 collagenase (type D, Roche
Molecular Biochemicals) and the Ca2+ concentration was
gradually increased during digestion. After enzymatic digestion,
the hearts were perfused for 10 min with solution A and ventricles
were cut into several pieces before myocytes were separated by
filtration through a nylon mesh.
Stimulation of Cardiomyocytes
To avoid the interference from endogenous adenosine, adenosine
deaminase (5 units/ml) was present under all experimental
conditions. In order to get an insight into the signaling via
A2A-AR we used the following highly selective antagonists for
pre-incubation: 1 µM DPCPX (A1-AR antagonist) or 1 µM ZM
241385 (A2A-AR antagonist). For subsequent stimulation activity
1 µM CGS 21680 [A2A-AR agonist (Boknik et al., 2009)] or
isoproterenol was added for 10 min at 37◦C. After denaturation
with 0.1 M HCl at 95◦C and centrifugation the supernatant was
stored at −20◦C for cAMP quantification and the pellet was
dissolved in 0.1 M NaOH for subsequent determination of the
protein concentration by the assay according to Bradford. For
determination of the phosphorylation state the incubation was
terminated by adding SDS solution according to Laemmli and
samples were subjected SDS PAGE and Western Blotting.
Contractile Function
Mice were anesthetized by i.p. injection of pentobarbital sodium
(50 mg kg−1) and hearts were excised. Right and left atria
were dissected from isolated A2A-AR transgenic and wild type
(WT) mice hearts and mounted in an organ bath. Left atrial
preparations were continuously electrically stimulated (field
stimulation) with each impulse consisting of 1 Hz, with a
voltage of 10–15% above threshold and 5 ms duration. Right
atrial preparations were allowed to contract spontaneously.
The bathing solution contained (in mM) NaCl 119.8, KCl
5.4, CaCl2 1.8, MgCl2 1.05, NaH2PO4 0.42, NaHCO3 22.6,
Na2EDTA 0.05, ascorbic acid 0.28 and glucose 5.0, continuously
gassed with 95% O2 and 5% CO2 and maintained at 35◦C
resulting in a pH of 7.4. Signals detected via an isometric
force transducer were amplified and continuously recorded.
CGS 21680, ZM 241385or isoproterenol (1 µM each) were
cumulatively applied with approximately 20 min for each
compound. Contraction experiments were performed after
addition of adenosine deaminase (1 µg ml−1) and DPCPX
(1 µM) to avoid interference from endogenous adenosine or A1
adenosine receptor activation.
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Langendorff-Perfused Hearts
Heart preparations were utilized as described previously
(Kirchhefer et al., 2014). Mice were anesthetized intraperitoneally
with 2.0 g kg−1 body weight urethane and treated with 1.5 units
of heparin. The hearts were removed from the opened chest,
immediately attached by the aorta to a 20-gauge cannula, and
perfused retrogradely under constant pressure of 50 mmHg with
oxygenized Krebs-Henseleit buffer (37.4◦C) containing 118 mM
NaCl, 25 mM NaHCO3, 0.5 mM Na-EDTA, 4.7 mM KCl, 1.2 mM
KH2PO4, 1.2 mM MgSO4, 2.5 mM CaCl2, and 11 mM glucose
in an isolated heart system (Hugo Sachs Elektronik, March-
Hugstetten, Germany). The heart preparations were allowed
to equilibrate for 30 min before measurements. Hearts were
stimulated at 8 Hz and heart rate, aortic pressure, and LV
pressure were measured and monitored continuously. The first
derivative of LV pressure (+dP/dt and −dP/dt) was calculated
(ISOHEART Software, Hugo Sachs Elektronik). To generate
global ischemia, the perfusion was stopped for 20 min (or 40 and
60 min, respectively) and thereafter the hearts were reperfused for
40 min.
Quantification of cAMP
Measurements of intracellular cAMP levels were performed by
using the Biotrak direct enzyme immunoassay (GE Healthcare,
Amersham, Chalfont St. Giles, United Kingdom) according to the
manufacturer’s instructions. The cAMP containing supernatant
was acetylated (1:40 with acetylation reagent, 1 volume acetic
anhydride + 2 volume triethylamine), and divided into the
donkey anti-rabbit IgG coated wells of a microtiter plate prefilled
with anti-cAMP serum. Competition between unlabeled cAMP
in the sample and a fixed quantity of peroxidase-labeled cAMP,
for a limited number of binding sites on the cAMP specific
antibody allowed quantification of intracellular cAMP.
Radioligand Binding Experiments
Freshly obtained ventricular tissue was manually minced in small
slices. Homogenization was performed at 4◦C with Polytron
(PT-MR 3000, Kinematica, Lucerne, Switzerland) three times for
30 s at the speed of 20,000 rpm in buffer A, containing sucrose
250 mM, histidine 30 mM (pH = 7.4) and thereafter using
Virsonic 100 (VirTis, Gardiner, NY, United States) for 2 s. This
suspension was centrifuged for 10 min at 1,500 × g and 4◦C
(Varifuge 3.0R, Heraeus, Hanau, Germany). The supernatant was
centrifuged at 45,000 × g (Beckman Avanti J-20XP, Beckman
Coulter, Palo Alto, CA, United States). The resulting supernatant
was stored at −20◦C. The pellet was resuspended in buffer B,
containing KCl 600 mM, histidine 30 nM (pH = 7.0) and again
centrifuged for 45 min at 64,000× g. The pellet was resuspended
in 250 µl buffer C, containing sucrose 250 mM, histidine 10 mM
(pH = 7.0) and stored at −80◦C until it was used for ligand
binding experiments.
The density of A2A-AR was determined using [3H]-CGS
21680. Membrane proteins were diluted to the concentration of
2 µg µl−1. The binding assays contained 40 µg of membranes in
A2A-TG and 400 µg in WT and in addition 8 nmol of [3H]-CGS
21680 in a final volume of 200 µl (A2A-TG) and 2 ml (WT),
which contained also 10 U ml−1 adenosine deaminase.
Unspecific binding was determined by addition of 1 µM ZM
241385. Binding assay was performed by incubation at 37◦C
for 90 min. Initially, the experiments for time dependency of
ligand association were performed for 15–120 min. Furthermore,
protein linearity was measured in the range of 20–120 µg
protein. In order to determine Bmax and KD 16 increasing
concentrations of [3H]-CGS 21680 from 0.1 to 20 nM were
used. For assessment of the specificity of radioligand binding
incubations in the presence of the A1-AR antagonist PSB36
(100 nM) as well as of the A3-AR antagonist MRS1220
were performed. Incubations were terminated by filtration
(filter type GF/52, Schleicher und Schuell, Dassel, Germany).
Radioactivity bound to the filters was determined by adding
5 ml scintillation fluid (Ultima Gold, Perkin Elmer, Rodgau,
Germany) in a counter (Canberra Packard 1600TR, Dreieich,
Germany).
Data Analysis
Data shown are means± SE. Statistical significance was estimated
by analysis of variance followed by Bonferroni’s t-test or using
the χ2-test as appropriate. A p-value < 0.05 was considered as
significant.
Drugs and Materials
All other chemicals were of analytical grade. Deionized water was
used throughout the experiments. Stock solutions were freshly
prepared daily.
RESULTS
A2A-AR Overexpression
In transgenic mice which overexpress the A2A-AR, we noted
that the A2A-AR could be detected on the protein level for the
following reasons. First of all, using very sensitive radioligand
binding experiments, we could detect binding of the [3H]-
labeled A2A-AR-agonist CGS 21680 samples form A2A-TG
hearts. This binding of [3H]-labeled A2A-AR-agonist CGS 21680
could be almost completely blocked by addition of the (non-
radioactively labeled) A2A-AR-antagonist ZM 241385, whereas
(non-radioactively labeled) A1-AR-antagonist PSB36 or (non-
radioactively labeled) A3-AR-antagonist MRS 1220 did not affect
the binding of [3H]-CGS 21680. Interestingly, under the same
experimental conditions used in samples from A2A-TG heart,
no specific binding of A2A-AR using the [3H]-labeled A2A-
AR-agonist CGS 21680 could be established in samples of the
hearts from WT littermates (Figure 1A). Secondly, the A2A-
AR could be visualized using immunohistology in A2A-TG
hearts. We tentatively identified the localization of the receptor
in A2A-TG to the vicinity of the sarcolemma (Figure 1B).
Relative heart weight, an established parameter of cardiac
hypertrophy, did not differ in whole hearts, ventricles or right
atria between A2A-TG and WT (Table 1). These data exclude
a cardiac hypertrophy of A2A-AR hearts at the two time points
studied.
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FIGURE 1 | (A) Radioligand binding studies in membrane fraction of
A2A-AR-overexpressing animals. The experiments were performed as
described in Section “Materials and Methods.” The binding of [3H]-labeled
A2A-AR-agonist CGS 21680 could be almost completely blocked by addition
of A2A-AR-antagonist ZM 241385, whereas A1-AR-antagonist PSB36 and
A3-AR-antagonist MRS 1220 did not affect the binding of [3H]-CGS 21680.
No specific binding was detectable in membrane fraction from WT animals.
(B) Immunohistological staining of ventricular tissue from
A2A-AR-overexpressing and wild type (WT) animals. A2A-AR was visualized
using a monoclonal antibody against A2A-AR and goat anti-mouse antibody
conjugated to Alexa Fluor 594 (red, upper row). The nuclei were
counterstained using DAPI (blue). Note staining of cardiomyocytes from
A2A-AR animals, mainly in the vicinity of the sarcolemma. Lower row: negative
controls with omission of the primary antibody. ?p < 0.05 vs. [3H]-CGS 21680
alone.
Expression of Sarcoplasmic and
G Proteins
The expression of CSQ (calsequestrin), SERCA [sarcoplasmic
reticulum (SR) Ca2+ ATPase 2a], and triadin and junctin (both
proteins located to the junctional SR), were unchanged between
WT and A2A-TG. However, PLB (phospholamban) expression
was tentatively but not significantly increased in A2A-TG and
is currently regarded as unchanged. Interestingly, at weeks 12
and 30 the expression of Gsα was lower in A2A-TG compared
to WT ventricles (Table 2). On the opposite note, in ventricle
from 30 weeks of A2A-TG mice an increase of Giα proteins
TABLE 1 | Relative weight [with regard to body weight (BW)] of whole hearts
(HW/BW), ventricles (V/BW), right atria (RA/BW) and left atria (LA/BW) in wild type
(WT) and A2A-AR overexpressing animals at the age of 12 and 30 weeks.
12 weeks 30 weeks
WT (n = 65) A2A-AR
(n = 51)
WT (n = 32) A2A-AR
(n = 36)
HW/BW (mg/g) 4.79 ± 0.06 4.73± 0.06 4.88 ± 0.07 4.89± 0.11
V/BW (mg/g) 4.08 ± 0.04 4.03± 0.06 4.05 ± 0.05 4.11± 0.02
RA/BW (mg/g) 0.37 ± 0.01 0.38± 0.01 0.38 ± 0.01 0.41± 0.02
LA/BW (mg/g) 0.18 ± 0.01 0.15± 0.02 0.17 ± 0.01 0.17± 0.01
No significant differences were noted between WT and A2A-AR overexpressing
animals.
TABLE 2 | Expression of cardiac regulatory proteins in ventricles of wild type (WT)
and A2A-AR overexpressing animals at the age of 12 and 30 weeks.
12 weeks 30 weeks
WT A2A-AR WT A2A-AR
CSQ 100 ± 11 100 ± 11 100 ± 7 89 ± 5
Gsα 100 ± 6 64 ± 4∗ 100 ± 7 66 ± 6∗
Giα 100 ± 11 109 ± 10 100 ± 10 148 ± 13∗
JCN 100 ± 15 99 ± 15 100 ± 9 109 ± 11
PLB 100 ± 15 148 ± 23 100 ± 11 140 ± 16
SERCA 100 ± 16 119 ± 20 100 ± 10 125 ± 11
TRD 100 ± 16 100 ± 15 100 ± 6 120 ± 19
Data are given as % of expression in corresponding WT animals (n = 6 each). CSQ,
calsequestrin; Gsα, α-subunit of stimulatory G protein; Giα, α-subunit of inhibitory G
protein; JCN, junctin; PLB, phospholamban; SERCA, sarcoendoplasmatic Ca2+-
ATP-ase; TRD, triadin. ∗p < 0.05 vs. corresponding WT.
was detected, but not at age 12 weeks or in atrial preparations
(Table 2).
Receptor Signaling
The A2A-AR agonist CGS 21680 concentration-dependently
increased the cAMP content in ventricular cardiomyocytes from
A2A-TG but not in WT cardiomyocytes (Figure 2A). The
increase in cAMP content in the presence of 1 µM CGS 21680
under these conditions was similar to the response of a maximum
effective concentration (1 µM) of the β-adrenoceptor agonist
isoproterenol (Figure 2B). These findings are consistent with the
fact that we measured a concentration dependent effect of CGS
21680 on phospholamban phosphorylation in isolated ventricular
cardiomyocytes from A2A-TG but not WT hearts (Figure 2C).
We used in these experiments adenosine deaminase (ADA)
that is an enzyme that rapidly degrades adenosine to inosine.
Inosine is not an agonist at adenosine receptors. The inclusion
of ADA was, in our hands, crucial in order to detect changes in
protein phosphorylation (see Figure 2 in Gupta et al., 1993a).
Importantly, we also noted a similar increase in isoproterenol-
induced phospholamban phosphorylation in cardiomyocytes
from A2A-TG and WT (Figure 2D). Moreover, it is noteworthy
that the maximum increase in phospholamban phosphorylation
was similar in WT in the presence of isoproterenol vs. CGS 21680
in A2A-TG cardiomyocytes (Figure 2D). In addition, we also
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FIGURE 2 | (A,B) cAMP content in isolated ventricular cardiomyocytes from WT and A2A-AR-overexpressing animals. cAMP content was determined by Biotrak
direct Enzymimmunoassay. Note concentration dependent increase of cAMP content by A2A-AR agonist CGS 21680 in A2A-AR cardiomyocytes (A); this effect
could be completely blocked by A2A-AR antagonist ZM 241385. The effect of β-adrenoceptor agonist isoproterenol on cAMP content did not differ between WT and
A2A-AR (B). (C,D) Phosphorylation of phospholamban at serine-16 (pPLB). (E,F) Phosphorylation of the inhibitory subunit of troponin (pTnI). The phosphorylation
state of PLB and TnI was assessed by phosphorylation specific antibodies. The signals obtained using phosphorylation specific antibodies were normalized to the
corresponding protein expression. Note concentration dependent increase of pPLB (C) and pTnI (E) by A2A-AR agonist CGS 21680 in A2A-AR cardiomyocytes;
these effects were abolished by A2A-AR antagonist ZM 241385. The effects of isoproterenol on protein phosphorylation were comparable in WT and A2A-AR (D,F).
?p < 0.05 vs. Ctr; #p < 0.05 vs. WT.
noted a similar increase in CGS 21680-induced phosphorylation
of troponin I in ventricular cardiomyocytes from A2A-TG
hearts but not from WT hearts (Figure 2E). Likewise, it
is notable that isoproterenol increased the phosphorylation
of troponin I not only in A2A-TG cardiomyocytes but also
WT cardiomyocytes (Figure 2F). Furthermore, the maximum
increase in TnI phosphorylation was similar in WT in the
presence of isoproterenol vs. CGS 21680 in A2A-TG myocytes
(Figure 2F). Moreover, the increase of cAMP-content and protein
phosphorylation in A2A-TG in the presence of the A2A-AR
agonist CGS 21680 could be attenuated by the additional presence
of the A2A-AR antagonist ZM 241385 (Figure 2, bar diagrams).
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TABLE 3 | Basal force of contraction (FOC) in electrically driven left atria and basal
beating rate (BR) in spontaneously beating right atria at the age of 12 and
30 weeks in wild type (WT) and A2A-AR overexpressing animals.
12 weeks 30 weeks
WT A2A-AR WT A2A-AR
FOC (mN) 2.49 ± 0.25 (19) 2.91 ± 0.25 (23) 3.23 ± 0.23 (19) 3.69 ± 0.20# (25)
BR (bpm) 441 ± 12 (12) 469 ± 22 (8) 410 ± 27 (11) 496 ± 16∗ (10)
The measurements were performed after preincubation with adenosine deaminase
(30 min, 1 µg/ml) to avoid interference from endogenous adenosine. Numbers of
atria are given in parentheses. ∗p < 0.05 vs. corresponding WT; #p < 0.05 vs.
A2A-AR at the age of 12 weeks.
Contractility
The mean values of developed tension under basal conditions (no
exogenous pharmacological stimulation) in electrically driven
left atrial preparations (12 and 30 weeks) were higher at
both ages in A2A-TG than WT but did not gain statistical
significance (Table 3). However, basal beating rate in A2A-TG
was higher than in WT (30 weeks Table 3) Contractile studies
in the organ bath were performed in the additional presence
of the A1-AR antagonist DPCPX (Neumann et al., 1989).
This was done in order to exclude possible interference of
any residual adenosine released from cells with the A1-AR
(stimulation of A1-AR in the atrium exerts negative inotropic
and negative chronotropic effects [mouse (Boknik et al., 1997)].
At weeks 12 and 30, the A2A-AR agonist CGS 21680 (1 µM)
increased force of contraction in electrically stimulated A2A-
TG left atrial preparations but not in electrically stimulated
WT atrial preparations (Figure 3A). In electrically stimulated
A2A-TG left atrial preparations, the positive inotropic effects
of CGS 21680 (1 µM) were attenuated by the A2A-AR
antagonist ZM 241385 (1 µM, Figure 3A). Similarly, 1 µM
CGS 21680 was able to increase the beating rate at 12
and 30 weeks in spontaneously beating A2A-TG right atrial
preparations but not in spontaneously beating WT right atrial
preparations (Figure 3B). This increase in beating rate in
spontaneously beating A2A-TG right atrial preparations was
attenuated by the A2A-AR antagonist ZM 241385 (1 µM,
Figure 3B).
β-Adrenergic Stimulation
In A2A-TG and WT, invasively left ventricular function was
assessed by a catheter while drug was continuously infused
with a syringe pump into the jugular vein. The increase
of the beating rate to infusion of dobutamine (a clinically
used β-adrenoceptor agonist) was similar in A2A-TG and
WT (Figure 4A). Basal left +dP/dT was higher in A2A-
TG compared to WT animals (Figure 4B). However, in
WT, dobutamine increased +dP/dT to a higher extent than
in A2A-TG (Figure 4B). In subsequent echocardiographic
studies, basal heart rate and interventricular systolic septum
thickness were increased in A2A-TG compared to WT. However,
the effects of β-adrenoceptor agonist isoproterenol on both
parameters were comparable between WT and A2A-TG animals
(Figure 5).
Ischemia/Reperfusion Experiments
Global ischemia was induced in paced (8 Hz) isolated
Langendorff-perfused hearts by complete stop of the perfusion.
Hearts were paced because differences in heart rate, alone,
might influence contractility. Basal heart rates before pacing
amounted to 421.5 ± 14.5 bpm for WT and 467.8 ± 11.7 bpm
for TG (p < 0.05 vs. WT, n = 5–7). During global ischemia
(20 min duration), contractile response (here +dP/dt) rapidly
stopped (Figure 6A). Protective effects were smaller but also
present after 40 and 60 min of global ischemia and reperfusion
(Figures 6B,C). Notably, basal rates of pressure development
were higher in A2A-TG than in WT (6,097.3 ± 213.9 mmHg/s
vs. 3,657.7 ± 144.7 mmHg/s, p < 0.05 vs. WT, n= 5–7). Upon
reperfusion, cardiac contractile response gradually resumed and
relative similar pressure values were reached as before the
ischemia in A2A-TG and WT (Figure 7A). It is noteworthy
that diastolic function is quite sensitive to ischemia in A2A-TG
(Figure 7B) and the increase in diastolic pressure and its
normalization as well as increase and normalization of rates of
pressure development were sensitive to 100 nM SCH 442416, an
A2A-AR antagonist (Figures 7A,B). Moreover, CGS 21680 was
able to hasten and elevate the percentile restoration of ventricular
+ dP/dT (Figure 7C).
DISCUSSION
In case of β-adrenergic stimulation and hypoxia, the amount
of extracellular adenosine increases in the coronary system
(Bardenheuer et al., 1987). Adenosine concentrations are much
higher in cardiomyocytes compared to in the extracellular space.
Thus, there is a huge concentration gradient for adenosine across
the cell membrane and if for example during a myocardial
infarction a necrosis occurs, a large amount of adenosine can be
released from dying cardiomyocytes.
Adenosine can be a degradation product of ATP but it can
also be produced de novo. Finally, adenosine deaminases are
responsible for metabolizing and thus inactivating adenosine.
Adenosine acts via adenosine receptors. All adenosine receptors
are a subgroup of P-purinoceptors which are separated further
into P1 - or P2 -purinoceptors (Shryock and Belardinelli,
1997; Burnstock, 2017). P1-purinoceptors are more sensitive
to adenosine than to ATP, the opposite holds true for P2-
purinoceptors (Shryock and Belardinelli, 1997; Burnstock, 2017).
We succeeded in expressing exogenous A2A-AR in
cardiomyocytes: importantly we can only detect radioligand
binding to the A2A-AR in the A2A-TG heart but not in WT heart.
None of the biochemical or physiological parameters studied
in an integrated and fairly complete approach supports the
functional presence of A2A-AR in WT myocytes, e.g., A2A-AR
agonists did not increase cAMP, protein phosphorylation, beating
rate or force of contraction in cardiomyocytes or isolated cardiac
preparation from WT mouse hearts. In contrast, a selective
A2A-AR agonist CGS 21680 increased cAMP content, protein
phosphorylation and contractility in A2A-TG preparations.
In genetically modified hearts, homeostatic changes in the
expression of other genes occur (Engelhardt et al., 2001;
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FIGURE 3 | (A) Force of contraction (FOC) in isolated electrically driven left atria. (B) Beating frequency (BF) in isolated spontaneously beating right atria. The
contraction experiments were performed in the presence of A1-AR antagonist DPCPX (1 µM). Note the higher basal BF and the increase of FOC and BF by A2A-AR
agonist CGS 21680 in atria of A2A-AR overexpressing animals. These effects were abolished in the presence of A2A-AR antagonist ZM 241385. ?p < 0.05 vs. Ctr;
#p < 0.05 vs. WT; +p < 0.05 vs. CGS 21680 alone.
FIGURE 4 | Hemodynamic parameters assessed by left ventricular catheterization in anesthetized WT and A2A-AR overexpressing animals as described in Section
“Materials and Methods.” Effects of dobutamine on beating frequency (BF, A) and maximum rate of left ventricular pressure development (+dP/dt, B). Note the higher
basal +dP/dt and the lack of dobutamine effect on +dP/dt in A2A-AR overexpressing animals. ?p < 0.05 vs. Ctr; #p < 0.05 vs. WT.
Lankford et al., 2002). Similar homoeostatic gene changes are
plausible in the present transgenic model. Hence, we interpret
the decrease in Gs as a protection against persistent basal
activity of the A2A-AR leading to chronic elevation of AC
activity and cAMP levels. Likewise, it is tempting to assume
that the increased Gi levels in order to decrease cAMP levels
to normal levels. The unchanged expression of main Ca2+
handling proteins of the SR facilitates the interpretation of
our contractile data and may be seen in light of our previous
work where we studied the function of for example triadin
or junctin overexpressing mice (Kirchhefer et al., 2001, 2003,
2004a,b, 2006, 2007; Buchwalow et al., 2004; Kirchhof et al.,
2007).
There are a number of studies in vitro and in vivo showing
the overexpression of a Gs coupled receptor per se can
increase the coupling of receptor and cAMP accumulation. This
can result in increased basal effects of the generated cAMP
and manifests itself in an increase in basal cAMP and/or
increase in PLB phosphorylation, increased basal contraction
in left atrial preparations (or intact catheterized hearts of on
echocardiography) and/or increased beating rate in isolated right
atrial preparation (or in isolated perfused hearts or catheterized
hearts of echocardiography). We reported this chain of events
before for 5HT4 receptor overexpressing mice (Gergs et al., 2013).
In part these alterations are present in this mouse model like
an increase in basal beating rate (isolated atrial preparations,
catheterized hearts, echocardiography).
The continuous stimulation of cAMP content by the
overexpressed A2A-AR might explain why higher beating rates
are noted in 30 week old A2A-TG right atrial preparations.
It is possible that the compensatory mechanisms detected and
discussed above lose their effectiveness at this age (but note that
they are apparently sufficient to keep parameters in the range of
WT at age 12 weeks).
Our interpretation of a functional A2A-AR expression (or
overexpression, depending on data interpretation) is supported
by the fact that an A2A-AR agonist increases force in left atrial
preparations and beating rate in isolated right atrial preparations.
Consistent with this the inotropic and chronotropic effects could
be reduced by an appropriate antagonist.
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FIGURE 5 | Hemodynamic parameters assessed by Doppler echocardiography in anesthetized WT and A2A-AR overexpressing animals. Note the increased basal
beating frequency (A) and interventricular systolic septum thickness (IVSs, B) in A2A-AR overexpressing animals. The effects of β-adrenoceptor agonist isoproterenol
on both parameters were comparable between WT and A2A-AR overexpressing animals. ?p < 0.05 vs. Ctr; #p < 0.05 vs. WT.
Others have shown that A1-AR overexpression as well as
A3-AR receptor overexpression can protect cardiac contractility
against short term ischemia [preconditioning (Matherne et al.,
1997; Black et al., 2002)].
Others have reported before on a constitutive (Chan et al.,
2008) or inducible overexpression (Hamad et al., 2010) of the
human A2A-receptor in the mouse heart. Our data confirm but
also extend this previous work: like us they noted an increase in
the heart rate in TG.
In contrast to our data they noted cardiac hypertrophy
(Table 1; Chan et al., 2008). Similar to Chan et al. (2008)
we detected histologically A2A-AR overexpression in myocytes,
increased expression of A2A-AR in Western Blots, and increased
levels of Giα and increased basal contractility (in invasive left
ventricular measurements prior to any drug application). We
extend those data (besides that we used a similar but not identical
promoter to drive cardiomyocyte specific overexpression) by
describing a reduced expression of Gs in TG, studying isolated
atrial preparations (elucidation the regional cardiac effects of
A2A-AR-overexpression) and by studying the signal transduction
in more detail. We concur with their data that cAMP (they
measured adenylyl cyclase activity) is not increased in TG
under basal conditions and therefore basal phosphorylation
state of TnI and phospholamban was not enhanced (which
they did not measure). We further extend their work by
showing that the overexpressed A2A-receptor exhibits the
expected pharmacology: namely the A2A-AR agonist CGS 21680
concentration dependently increased cAMP content in TG (but
not WT) and likewise, probably by stimulating the activity of
PKA, leads to increased phosphorylation state of phospholamban
on its PKA sensitive phosphorylation site and in increased
phosphorylation state addition of TnI.
While the group of Feldman elegantly used their model
to study in vivo functional interaction of A1A coexpression
with A2A-receptors (Chan et al., 2008), the protective role
of A2A in pressure overload (aortic banding: Hamad et al.,
2012) or protection against the cardiodepressant role of chronic
Adriamycin treatment (Hamad et al., 2010), we used our
model to initiate a first study on the putative protective
role of A2A-overexpression in reperfusion of the heart, which
to the best of our knowledge has not been studied before,
while a protective role of A2A-AR in other species using
pharmacological stimulation has been described. We would
argue that overexpression of the receptor adds substantially on
our mechanistically knowledge in reperfusion injury because,
pharmacological stimulation will not allow delineating which
cells are involved in a putative protective effect of A2A-
receptors: they are expressed (at least functionally) not only
in cardiomyocytes but also in cardiac endothelial cells and
smooth muscle cells. Hence, any effect we observe in perfused
hearts (in the absence of drug application) is probably due to
the action of endogenously produced adenosine on the human
A2A-AR in cardiomyocytes. Another advantage of our approach
(compared to other reports, e.g., Jordan et al., 1997) is that
we used isolated buffer perfused hence A2A-receptors in the
blood cannot confound our data (which can occur, see, Yang
et al., 2005). Others have failed to see any effect of A2A-KO
vs. WT in isolated perfused heart on reperfusion injury (Zhan
et al., 2011, review: McIntosh and Lasley, 2012). Based on
our data, we would argue that it might be due to the loss
of A2A not only in cardiomyocytes (which we would predict
to be deleterious) but also on endothelial, smooth muscle and
fibroblasts (for review cell specific expression of A2A-AR, e.g.,
McIntosh and Lasley, 2012). It would be interesting to generate
and study reperfusion in mice with cardiomyocytes specific
A2A-AR KO.
Finally, the data on ischemia may suggest that the A2A-AR
may play a protective role of this receptor in ischemia. It might be
speculated that alterations of this receptor occur physiologically
in myocardial ischemia (for instance during infarction and
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FIGURE 6 | Comparison of 20 min (A), 40 min (B), and 60 min (C) of global
ischemia in isolated Langendorff-perfused hearts from WT and A2A-AR
overexpressing animals. Maximum rate of left ventricular pressure
development (+dP/dt) is presented as % of basal value. ?p < 0.05 vs. WT.
stenting of the vessel). These receptors may therefore be a target
for pharmacological treatment of reperfusion injury. However,
more detailed studies are called for and are expected with interest.
Moreover, one can ask whether this model has (patho)-
physiological relevance. In this regard it might be of interest
that during ischemia in isolated perfused hearts the expression
of A2A-AR increases (Morrison et al., 2006). A2A agonists like
regadenoson are clinically used to detect latent ischemia in
patients (Cerqueira et al., 2008).
Study Limitations
Furthermore, the direct comparison with the human situation
is not easy. In earlier work, we reported that adenosine can in
some atrial samples from patients exert a positive inotropic effect
(Gergs et al., 2009). However, the effect was A1 receptor mediated.
We have not been able to perform similar experiments in
FIGURE 7 | Hemodynamic parameters during global ischemia with
subsequent reperfusion assessed in isolated Langendorff-perfused hearts
from WT and A2A-AR overexpressing animals. (A) Maximum rate of left
ventricular pressure development (+dP/dt) as % of basal value with and
without the A2A-AR antagonist SCH 442416 (SCH, 100 nM). (B) Left
ventricular end diastolic pressure with and without the A2A-AR antagonist
SCH 442416 (SCH, 100 nM). (C) Effect of A2A-AR agonist CGS 21680 (1 µM)
administered during reperfusion on +dP/dt in A2A-AR overexpressing hearts.
Note the higher basal +dP/dt, markedly prolonged time to ischemic
contracture as well as the additional effect of A2A-AR agonist CGS 21680 on
the +dP/dt in A2A-AR overexpressing hearts during reperfusion. ?p < 0.05 vs.
WT; #p < 0.05 vs. A2A-AR.
human ventricular tissue (for lack of material at our institutions).
However, some years ago we reported at least an increase in
the mRNA of A2A-AR in failing human ventricular samples
compared to non-failing (Stein et al., 1998). Thus, it is tempting
to speculate that A2A-AR may sustain contractility in end stage
human heart failure. Hence, A2A-AR may serve a physiological
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role in humans and, as shown for adenoviral expression of
adenylate cyclase, genetic manipulation of A2A-AR may offer a
novel venue for treating human heart failure.
CONCLUSION
We describe a transgenic mouse with A2A-AR overexpression to
cardiomyocytes using the established alpha myosin heavy chain
promoter. Moreover, transgenic A2A-AR is functional after drug-
induced stimulation to increase force and beating rate in mouse
hearts or mouse heart preparations and the transgenic A2A-AR
can protect the mouse heart against ischemia.
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